{"entity":{"id":"micromet","kind":"company","name":"Micromet","aka":["Micromet, Inc.","Micromet AG"],"tldr":"Micromet developed BiTE antibodies, which link the body's T cells to cancer cells so the T cells can kill them. Amgen bought it in 2012 for blinatumomab, a BiTE antibody for acute lymphoblastic leukaemia.","summary":"Micromet was a Nasdaq-listed (MITI) biotechnology company founded in Germany, with research and development in Munich and headquarters in Rockville, Maryland, built on its BiTE (bispecific T cell engager) antibody platform. Amgen agreed on 26 January 2012 to acquire it for $11 a share in cash, valuing it at about $1.16 billion, for blinatumomab, then in Phase 2 for acute lymphoblastic leukaemia and also in development for non-Hodgkin lymphoma. Amgen completed its tender offer on 7 March 2012 with 88.34 per cent of shares tendered. Atlas Venture lists Micromet as making biologics for cancer, sold to Amgen in 2012.","asOf":"2026-11-04","links":[{"label":"Amgen to acquire Micromet (SEC exhibit, 26 January 2012)","url":"https://www.sec.gov/Archives/edgar/data/318154/000119312512024302/d288301dex992.htm"},{"label":"Amgen completes tender offer (SEC exhibit, 7 March 2012)","url":"https://www.sec.gov/Archives/edgar/data/318154/000119312512100174/d312184dex99a5.htm"},{"label":"Atlas Venture portfolio entry","url":"https://atlasventure.com/portfolio/"}],"tags":[],"related":[],"cancers":["all-leukemia","non-hodgkin-lymphoma"],"sections":["immunotherapy"],"technologies":["t-cell-engager","bispecific-antibody"],"targets":[],"drugs":["blinatumomab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Founding year not stated in the sources read.","The existing OnCo drug record blinatumomab came from Micromet and can link here.","SEC records list CancerVax Corp as a former name of the Micromet, Inc. registrant; not added as an alias without a reading of why."],"hq":"Rockville, MD","country":"US","companyType":"biotech","stage":"acquired","investors":["atlas-venture"],"funding":[],"acquiredBy":"amgen"},"route":"/companies/micromet/","neighbours":{"cancer":[{"id":"all-leukemia","kind":"cancer","name":"Acute lymphoblastic leukaemia","route":"/cancers/all-leukemia/"},{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"}],"section":[{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"technology":[{"id":"bispecific-antibody","kind":"technology","name":"Bispecific antibodies","route":"/technologies/bispecific-antibody/"},{"id":"t-cell-engager","kind":"technology","name":"T-cell engagers (bispecific)","route":"/technologies/t-cell-engager/"}],"drug":[{"id":"blinatumomab","kind":"drug","name":"Blinatumomab","route":"/drugs/blinatumomab/"}],"company":[{"id":"amgen","kind":"company","name":"Amgen","route":"/companies/amgen/"},{"id":"atlas-venture","kind":"company","name":"Atlas Venture","route":"/companies/atlas-venture/"}]}}